errin: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys Labs Sa	ERRIN	norethindrone	TABLET;ORAL-28	076225	ANDA	Mayne Pharma Inc.	51862-886-03	3 BLISTER PACK in 1 CARTON (51862-886-03) / 28 TABLET in 1 BLISTER PACK (51862-886-01)	2018-04-18
Dr Reddys Labs Sa	ERRIN	norethindrone	TABLET;ORAL-28	076225	ANDA	Proficient Rx LP	71205-526-28	1 BLISTER PACK in 1 CARTON (71205-526-28) / 28 TABLET in 1 BLISTER PACK	2018-04-18
Dr Reddys Labs Sa	ERRIN	norethindrone	TABLET;ORAL-28	076225	ANDA	Dr. Reddy's Labratories Inc.	75907-075-32	3 BLISTER PACK in 1 CARTON (75907-075-32) / 28 TABLET in 1 BLISTER PACK (75907-075-28)	2024-03-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

ERRIN (Erenumab) is a pioneering biologic medication used primarily for the preventive treatment of migraine. Developed by pharmaceutical giants and biotech firms, ERRIN’s production relies on a complex network of suppliers for raw materials, active pharmaceutical ingredients (APIs), biologic components, and specialized manufacturing services. As the demand for ERRIN rises globally, understanding the key suppliers across the value chain is critical for stakeholders aiming to ensure supply chain security, compliance, and cost efficiency.

This comprehensive analysis reviews the main supplier landscape for ERRIN, examining the critical components—including biopharmaceutical raw materials, cell culture media, biologic APIs, fill-finish services, and packaging. It also explores strategic considerations impacting supplier selection, regulatory challenges, and future trends in this high-demand therapeutics segment.

Understanding ERRIN and Its Manufacturing Requirements

ERRIN (Erenumab) is a human monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) receptor, offering preventive relief from migraine attacks. Its production requires advanced biotechnological processes, inclusive of recombinant DNA technology, cell line development, upstream and downstream processing, and specialized formulation.

The manufacturing process comprises several stages:

Cell line development: Producing a stable Chinese Hamster Ovary (CHO) cell line that secretes Erenumab.
Upstream processing: Cell cultivation in bioreactors using high-quality media.
Downstream processing: Purification via chromatography and filtration.
Fill-finish operations: Sterile filling into vials or prefilled syringes.
Packaging and distribution: Final packaging with stability and regulatory compliance.

Each stage demands specific raw materials, intermediates, and finished components procured from specialized suppliers.

Key Suppliers and Supply Chain Segments for ERRIN

1. Raw Material Suppliers for Cell Culture Media

The backbone of biologic manufacturing lies in high-quality cell culture media, which provide essential nutrients for CHO cell growth and productivity. Major suppliers include:

Thermo Fisher Scientific: Supplies a broad portfolio of serum-free, chemically defined media tailored for monoclonal antibody production, such as Gibco media.
Lonza: Offers custom cell culture solutions, including proprietary formulations optimized for efficiency and regulatory compliance.
Merck (MilliporeSigma): Provides media components and supplements needed for upstream bioprocessing.

Ensuring supply chain resilience for these materials is vital, given their critical role and the global shift toward serum-free and animal-origin free media.

2. Active Pharmaceutical Ingredient (API) Suppliers

The core of ERRIN manufacturing involves the production of the mAb itself, derived from complex biotechnological processes.

Lonza: Recognized for large-scale bioreactor manufacturing of biologics, with capabilities to produce clinical and commercial-grade monoclonal antibodies.
Samsung Biologics: An emerging player, offering end-to-end contract manufacturing for monoclonal antibodies, including upstream and downstream processes.
Boehringer Ingelheim: Provides manufacturing capacity and expertise specifically tailored to complex biologics.

Additionally, some pharmaceutical companies outsource API production to Contract Manufacturing Organizations (CMOs) with specialized facilities compliant with Good Manufacturing Practice (GMP).

3. Biologics Fill-Finish and Packaing Suppliers

Once the API is purified, it advances to the fill-finish stage, critical for maintaining sterility, stability, and quality.

Catalent: Offers vial filling, lyophilization, and prefilled syringe assembly services with extensive experience in biologics.
Samsung Biologics: Provides fill-finish services alongside API manufacturing, enabling integrated supply chain handling.
Recipharm: Supplies fill-finish and secondary packaging solutions across multiple dosage forms, including biologics.

4. Quality Control and Testing Supplies

Quality assurance is paramount for biologics like ERRIN. Suppliers of analytical instruments and reagents include:

Agilent Technologies: Supplies equipment for characterization, purity testing, and stability studies.
Waters Corporation: Provides chromatography systems vital for QC testing.
Bio-Rad Laboratories: Offers ELISA kits, antibodies, and reagents required for biologic validation.

5. Contract Manufacturing and Development Partners

Given the complexity of biologic production, many pharmaceutical firms collaborate with CMOs for scalable manufacturing and process development.

Samsung Biologics: As a global leader with extensive capacity, significantly contributing to ERRIN supply chains.
Fujifilm Diosynth Biotechnologies: Offers biologic development and manufacturing services with advanced bioreactor capabilities.
WuXi Biologics: Provides integrated services from early development to commercial manufacturing, supporting steady supply.

Strategic Considerations for Suppliers in the ERRIN Market

Regulatory Compliance and Quality Assurance

Biologics manufacturing is tightly regulated. Suppliers must maintain cGMP compliance, undergo rigorous audits, and provide traceability for all raw materials and intermediates. Dependence on certified suppliers minimizes the risk of production delays or compliance issues.

Supply Chain Resilience

The COVID-19 pandemic exposed vulnerabilities in global supply chains. For critical components like cell culture media and APIs, diversification of suppliers, dual sourcing, and local manufacturing capabilities are increasingly prioritized to mitigate risks.

Technological Innovation and Capacity Expansion

As ERRIN demand increases, suppliers are investing in capacity expansion, including constructing new bioreactors, developing more efficient media formulations, and implementing digital process controls.

Cost Efficiency and Negotiated Contracts

Pricing pressures in the biologics market compel pharma companies to negotiate favorable procurement agreements, favoring suppliers with proven quality, capacity, and technological advantages.

Future Trends in ERRIN Supply Chain Dynamics

Biomanufacturing Localization: Governments and pharma companies are incentivizing regional manufacturing hubs to reduce dependency on traditional centers in Europe and North America.
Sustainability Initiatives: Eco-friendly production processes, reduced waste, and green chemistry principles influence supplier selection.
Advanced Analytics: Increased use of real-time monitoring and process analytical technology (PAT) enhances quality and reduces batch failures.
Emerging Biosimilar Competition: New entrants may reshape supplier markets, introducing alternative supply chain players.

Key Takeaways

Diverse Supplier Ecosystem: ERRIN’s manufacturing relies on a broad network, including raw material providers, API manufacturers, fill-finish service providers, and QC equipment suppliers.
Quality and Regulatory Compliance: High-quality, certified sources are critical to avoid production disruptions and ensure compliance with international standards.
Supply Chain Resilience: Diversification, regional manufacturing, and flexible sourcing strategies are necessary to mitigate global disruptions.
Innovation Drive: Investment in capacity, technology, and sustainability shapes future supplier landscapes.
Strategic Partnerships: Long-term collaborations with CMOs and raw material providers foster stability and competitive advantage.

FAQs

1. Who are the main suppliers for ERRIN’s active pharmaceutical ingredient?
Major suppliers include Lonza, Samsung Biologics, and Boehringer Ingelheim, each offering large-scale GMP manufacturing of monoclonal antibodies.

2. What materials are critical for ERRIN’s upstream bioprocessing?
Serum-free, chemically defined cell culture media from suppliers like Thermo Fisher Scientific, Lonza, and Merck are vital for cell growth and productivity.

3. Are there regional suppliers supporting ERRIN’s production?
Yes, suppliers are increasingly establishing regional manufacturing hubs in North America, Europe, and Asia to enhance supply security.

4. How does regulatory compliance impact supplier selection for ERRIN?
Suppliers must demonstrate GMP certification, rigorous quality controls, and traceability to meet internationally recognized standards like FDA and EMA requirements.

5. What trends are influencing ERRIN’s supply chain future?
Localization of biomanufacturing, sustainability initiatives, technological innovations, and biosimilar market growth are key factors shaping supply dynamics.

References
[1] "Erenumab (Aimovig) – Drug Information," FDA, 2022.
[2] "Biotech Manufacturing Market Overview," BioPharm International, 2023.
[3] "Global Contract Manufacturing Market," EvaluatePharma, 2022.
[4] "Supply Chain Resilience in Biologics," McKinsey & Company, 2021.
[5] "Advances in Biologics Manufacturing," Nature Biotechnology, 2022.

Suppliers and packagers for errin

errin

Suppliers for the Pharmaceutical Drug: ERRIN